Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
International prescribing practices in obsessive–compulsive disorder (OCD)
Human Psychopharmacology, Year 2016
Notification
URL copied to clipboard!
Description
Objectives: To assess rates of psychotropic medication use in patients with obsessive–compulsive disorder (OCD) in seven different countries on five continents and to compare these with international treatment guidelines. Methods: Researchers in the field of OCD were invited to contribute summary statistics on the characteristics of their patients with OCD and on their incidence of psychotropic use. Consistency of summary statistics across countries was evaluated. Results: The data came from Brazil (n = 955), Italy (n = 750), South Africa (n = 555), Japan (n = 382), Australia (n = 213), India (n = 202) and Spain (n = 82). The majority (77.9%; n = 2445) of the total sample of 3139 participants received a psychotropic medication. Consistent with international guidelines, selective serotonin reuptake inhibitors (SSRIs) were most commonly used (73.5%, n = 1796), but their use ranged from 59% in Australia to 96% in Japan. Clomipramine use varied from 5% in Japan and South Africa to 26% in India and Italy. Atypical antipsychotic use ranged from 12% in South Africa to 50% in Japan. Conclusions: Pharmacotherapy for OCD varied significantly across sites. Prospective studies are required to determine the cultural, pharmacoeconomic and pharmacogenomic factors that may play a role in the variation in prescribing practices internationally and whether these variations influence treatment outcomes. Copyright © 2016 John Wiley & Sons, Ltd.
Authors & Co-Authors
Brakoulias, Vlasios
Australia, Sydney
The University of Sydney School of Medicine
Starčević, Vladan
Australia, Sydney
The University of Sydney School of Medicine
Belloch Fuster, Amparo
Spain, Valencia
Universitat de València
Dell’Osso, Liliana
Italy, Pisa
Università Di Pisa
Fer rão, Ygor A.
Brazil, Porto Alegre
Universidade Federal de Ciencias da Saúde de Porto Alegre
Fontenelle, Leonardo F.
Brazil, Rio de Janeiro
Universidade Federal do Rio de Janeiro
Australia, Clayton
Faculty of Medicine, Nursing and Health Sciences
Lochner, Christine
South Africa, Stellenbosch
Stellenbosch University
Marazziti, Donatella
Italy, Pisa
Università Di Pisa
Martin, Andrew J.
Australia, Sydney
The University of Sydney
Matsunaga, Hisato
Japan, Nishinomiya
Hyogo Medical University
Miguel, Eurípedes Constantino
Brazil, Sao Paulo
Universidade de São Paulo
Reddy, Yemmigannur Chandrashekhar Janardhan
India, Bengaluru
National Institute of Mental Health and Neuro Sciences
Rosário, Maria Conceição Do
Brazil, Sao Paulo
Universidade Federal de São Paulo
Shavitt, Roseli Gedanke
Brazil, Sao Paulo
Universidade de São Paulo
Sundar, Arumugham Shyam
India, Bengaluru
National Institute of Mental Health and Neuro Sciences
Stein, Dan J.
South Africa, Stellenbosch
Stellenbosch University
Viswasam, Kirupamani
Australia, Sydney
The University of Sydney School of Medicine
Statistics
Citations: 23
Authors: 17
Affiliations: 12
Identifiers
Doi:
10.1002/hup.2541
ISSN:
08856222
e-ISSN:
10991077
Study Design
Cohort Study
Study Locations
South Africa